Clinical trial
Genetics of Ventriculo-arterial Discordance: Towards a PRECIsion Medicine in PEDiatric Cardiology
Name
RC21_0555
Description
Number of centres planned : 16 centres in France
Type of study / Study design : Research Involving the Human Person category 2.
Multicentric. Prospective
Planning of the study : Total duration: 22 years. Recruitment period: 24 months. Follow-up
time per patients : 20 years
Expected number of cases : 300 index cases: 150 single index cases and 150 trio families
Treatment, procedure, combination of procedures under consideration :
* Blood samples for genetic analyses collected at the inclusion visit for patients and parents in case of trio families
Schedule of different visits and examinations :
Inclusion visit:
* Collection of demographic, clinical data from the index case and parents
* DNA sampling for genetic research (biocollection) of the index case or family trio
* Completion of the quality of life questionnaire
Annual visit with a 20 year follow-up:
* Retrieval of data from the index case
* Completion of the quality of life questionnaire
Trial arms
Trial start
2022-09-07
Estimated PCD
2025-08-01
Trial end
2043-08-01
Status
Recruiting
Treatment
Genetic analyses: whole genome sequencing
Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
Arms:
Congenital heart disease
Size
600
Primary endpoint
Identification new genes/variants involved in congenital heart disease with transposition congenitally corrected of the great arteries, based on whole genome sequencing of familial trios.
24 months
Eligibility criteria
Inclusion Criteria:
* Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with healthy parents and no family history of congenital heart disease (familial trio)
* Or patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with or without a history of congenital heart disease (familial form or sporadic case)
* Affiliated or beneficiaries of a social security scheme or similar
* After obtaining oral consent from patients and/or parents if applicable
Parents (for family trios) :
- Biological parents of the child included in the PRECIPED study
Exclusion Criteria:
* Patients with transposition of the great arteries or transposition congenitally corrected of the great arteries with hypoplastic ventricle or atrioventricular and/or ventriculoarterial valve atresia
* Patient with an identified malformation syndrome
* Patients under guardianship/curatorship
* Patients with State Medical Aid
* Refusal of consent by the patient and/or one of the two parents
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': '600 participants (150 single cases and 150 trio families)', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 600, 'type': 'ESTIMATED'}}
Updated at
2024-03-21
1 organization
1 product
2 indications
Organization
Nantes University HospitalProduct
Genetic analysesIndication
Congenital Heart DefectIndication
Congenital